Skip to main content

Andrew Berchuck, MD

Andrew Berchuck, MD
James M. Ingram Professor of Gynecologic Oncology
Campus Mail: 25171 Morris Bldg, Durham, NC 27710
Phone: (919) 684-3765
Email: berch001@mc.duke.edu

Dr. Andrew Berchuck is Director of the Duke Division of Gynecologic Oncology and holds the James M. Ingram Distinguished Professorship. He is a practicing oncologist who is actively involved in the surgical and chemotherapy management of women with ovarian, endometrial and lower genital tract cancers. This includes minimally invasive laparoscopic surgical approaches. He also has developed a research program that focuses on the molecular-genetic alterations involved in malignant transformation of the ovarian and endometrial epithelium. He has published over 300 peer-reviewed papers in these areas. The objectives of his research include 1) identification of ovarian cancer susceptibility polymorphisms through a population-based case-control molecular epidemiologic study, and 2) use of genomic approaches  to elucidate the molecular heterogenetity of ovarian cancer. Thirty fellows and residents have worked in his lab, several of whom are now funded investigators. His research efforts have been recognized nationally and he has received awards for best oral presentation at the annual meetings of both the Society of Gynecologic Oncology and the International Gynecologic Cancer Society. Dr. Berchuck was awarded the Barbara Thomason Ovarian Cancer Research Professorship by the American Cancer Society in 2006. He has served as editor of several books in the field including Principles and Practice of Gynecologic Oncology. Dr. Berchuck also has a major commitment to national activities, and was President of the Society of Gynecologic Oncology in 2008. He served as chair of the scientific advisory committee of the Ovarian Cancer Research Fund (http://www.ocrf.org) in New York City. Finally, he is also head of the steering committee of the international Ovarian Cancer Association Consortium (OCAC), a group of 50 case-control studies that are working together to identify ovarian cancer susceptibility polymorphisms (www.srl.cam.ac.uk/consortia/ocac/index.html).

Education and Training

  • M.D., Case Western Reserve University, 1980

Research

Dr Berchuck is interested in the molecular pathogenesis of ovarian and endometrial cancer. 

View Publications

Publications

Berchuck, A, and Boyd, J. "Molecular basis of endometrial cancer." Cancer 76, no. 10 Suppl (November 15, 1995): 2034-2040. (Review)

Scholars@Duke

BERCHUCK, A, and BOYD, J. "MOLECULAR-BASIS OF ENDOMETRIAL CANCER." November 15, 1995.

Full Text

Evans, AC, Soper, JT, Clarke-Pearson, DL, Berchuck, A, Rodriguez, GC, and Hammond, CB. "Gestational trophoblastic disease metastatic to the central nervous system." Gynecol Oncol 59, no. 2 (November 1995): 226-230.

Scholars@Duke

Berchuck, A, and Bast, RC. "p53-based gene therapy of ovarian cancer: magic bullet?." Gynecol Oncol 59, no. 2 (November 1995): 169-170.

Scholars@Duke

Hurteau, JA, Woolas, RP, Jacobs, IJ, Oram, DC, Kurman, CC, Rubin, LA, Nelson, DL, Berchuck, A, Bast, RC, and Mills, GB. "Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer." Cancer 76, no. 9 (November 1, 1995): 1615-1620.

Scholars@Duke

Woolas, RP, Conaway, MR, Xu, F, Jacobs, IJ, Yu, Y, Daly, L, Davies, AP, O'Briant, K, Berchuck, A, and Soper, JT. "Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses." Gynecol Oncol 59, no. 1 (October 1995): 111-116.

Scholars@Duke

FUTRCAL, PA, GUMBS, C, BERCHUCK, A, and WISEMAN, RW. "FREQUENT ALLELIC DELETION OF CHROMOSOME 1P IN PRIMARY OVARIAN-CANCER - MAPPING OF 2 TUMOR SUPRESSOR GENE REGIONS AND PRELIMINARY-ANALYSIS OF CANDIDATE GENES." AMERICAN JOURNAL OF HUMAN GENETICS 57, no. 4 (October 1995): 11-11.

Scholars@Duke

Berchuck, A, Anspach, C, Evans, AC, Soper, JT, Rodriguez, GC, Dodge, R, Robboy, S, and Clarke-Pearson, DL. "Postsurgical surveillance of patients with FIGO stage I/II endometrial adenocarcinoma." Gynecol Oncol 59, no. 1 (October 1995): 20-24.

Full Text

LIU, JR, CONAWAY, M, RODRIGUEZ, GC, SOPER, JT, CLARKEPEARSON, DL, and BERCHUCK, A. "RELATIONSHIP BETWEEN RACE AND INTERVAL TO TREATMENT IN ENDOMETRIAL CANCER." OBSTETRICS AND GYNECOLOGY 86, no. 4 (October 1995): 486-490.

Full Text

Liu, JR, Conaway, M, Rodriguez, GC, Soper, JT, Clarke-Pearson, DL, and Berchuck, A. "Relationship between race and interval to treatment in endometrial cancer." Obstet Gynecol 86, no. 4 Pt 1 (October 1995): 486-490.

Scholars@Duke

Pages